医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

US FDA Extends License of the GVK BIO Biomarker Database

2013年02月04日 PM04:25
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (US FDA). The GOBIOM database, which has the latest and recently updated information on all the biomarkers reported in various clinical and preclinical studies, will be beneficial to the US FDA in its Biomarker Qualification Process.

The GOBIOM database is a comprehensive compilation of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 20,000 biomarkers comprising biochemical, genomic, imaging, metabolite, cellular and physiological markers, along with multiple data points comprising experimental, analytical, clinical and statistical data with their qualifications under different medical interventions.

Sreeni Devidas, Vice President, Sales & Marketing, Informatics, said, “The collaboration with the US FDA has helped GVK BIO in developing the safety biomarker content in GOBIOM. The interconnectivity between organ toxicities to the drug, dose and population was developed with equal emphasis on its preclinical qualification. Biomarker analysis tools were integrated into the database in a manner that has facilitated the user to make a comparative analysis between the biomarkers of their interest. We look forward to continue working and collaborating with the FDA with a view to enhancing the utility of the product further.”

About GVK BIO

GVK Biosciences (GVK BIO) is Asia’s leading discovery, research and development organization providing a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio and global clientele comprising more than 200 customers includes some of the global leading organizations in the fields of pharmaceuticals, biotechnology, agro, life-sciences as well as prestigious academic institutions. Please visit us at www.gvkbio.com to know more.

CONTACT

GVK Biosciences Private Limited
Sreeni Devidas
Vice President
– Business Development
T 443-838-6260
E sreeni.devidas@gvkbio.com
W
www.gvkbio.com
or
Sushant
Datta
DGM – Corporate Brand & Communications
T 0091 40
66929999
E sushant.datta@gvkbio.com
W
www.gvkbio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表